stoxline Quote Chart Rank Option Currency Glossary
  
Pluri Inc. (PLUR)
5.372  -0.378 (-6.57%)    05-12 16:00
Open: 5.7412
High: 5.77
Volume: 48,693
  
Pre. Close: 5.75
Low: 5.2601
Market Cap: 42(M)
Technical analysis
2025-05-12 4:51:05 PM
Short term     
Mid term     
Targets 6-month :  8.32 1-year :  9.72
Resists First :  7.13 Second :  8.32
Pivot price 5.2
Supports First :  4.8 Second :  3.35
MAs MA(5) :  5.23 MA(20) :  4.88
MA(100) :  4.5 MA(250) :  5.04
MACD MACD :  0.2 Signal :  0.1
%K %D K(14,3) :  47.8 D(3) :  47.2
RSI RSI(14): 57
52-week High :  7.13 Low :  3.32
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ PLUR ] has closed below upper band by 42.9%. Bollinger Bands are 127.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.77 - 5.8 5.8 - 5.82
Low: 5.2 - 5.23 5.23 - 5.25
Close: 5.32 - 5.37 5.37 - 5.41
Company Description

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Headline News

Tue, 29 Apr 2025
Pluri Inc. sets date for 2025 shareholder meeting - Investing.com

Mon, 28 Apr 2025
$13.5B Cacao Market Disruption: Pluri Acquires Cellular Agriculture Pioneer Kokomodo for Climate-Resilient Future - Stock Titan

Mon, 28 Apr 2025
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. - Yahoo Finance

Mon, 21 Apr 2025
DarioHealth Taps Israeli CFO Excellence Award Winner to Lead Next Growth Phase - Stock Titan

Thu, 17 Apr 2025
Pluri Inc. subsidiary loses $4.2 million NIAID contract - Investing.com

Tue, 08 Apr 2025
Pluri CEO Yaky Yanay on pioneering cell-tech solutions for global needs - Proactive financial news

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out -12 (M)
Shares Float 0 (M)
Held by Insiders 7e+006 (%)
Held by Institutions 3.43e+006 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 474000
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -3.69
Profit Margin 0 %
Operating Margin -2 %
Return on Assets (ttm) 679.4 %
Return on Equity (ttm) -37.5 %
Qtrly Rev. Growth 102.5 %
Gross Profit (p.s.) -8.29
Sales Per Share -126.43
EBITDA (p.s.) 197546
Qtrly Earnings Growth -2.147e+007 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value -1.46
Price to Sales -0.05
Price to Cash Flow 0
Stock Dividends
Dividend 8530
Forward Dividend 18050
Dividend Yield 158786%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android